Advertisement

Picture Berlin Partner Top News Noah Labs Raises $3m AI Telemonitoring 650x100px
Document › Details

Valanx Biotech GmbH. (10/29/24). "Press Release: Valanx Biotech and Fina Biosolutions Introduce ClickCRM for Rapid Conjugate Vaccine Development". Klosterneuburg & Rockville, MD.

Organisations Organisation Valanx Biotech GmbH
  Organisation 2 Fina Biosolutions LLC (FinaBio)
Products Product ClickCRM™ (Valanx Biotech / Fina Biosolutions)
  Product 2 vaccine technology
Person Person Lukesch, Michael (Valanx Biotech 202311 CEO + Founder)
     


Joint licensing agreement to commercialize ready-to-conjugate vaccine carrier protein CRM197 will enable rapid development of conjugate vaccines


VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, and Fina Biosolutions LLC (FinaBio), experts in conjugate vaccine development and conjugate chemistry, today announced the signing of a joint IP and licensing agreement. The companies will launch ClickCRM™, a ready-to-conjugate version of CRM197, an antigenic carrier protein used for making conjugate vaccines. The new product enables the rapid, high-efficiency conjugation of carrier proteins to polysaccharide antigens for the generation of conjugate vaccines.

Conjugate vaccines, such as the pneumococcal and meningococcal vaccines, have improved efficacy against bacterial infections compared with polysaccharide vaccines. Their enhanced immunogenicity is achieved through the conjugation of polysaccharide antigens to protein carriers. Using synthetic biology, FinaBio and VALANX have created ClickCRM, a product that will enable the precise conjugation of antigens to the widely used carrier protein, CRM197. ClickCRM has defined conjugation sites generated via the incorporation of synthetic amino acids compatible with third-generation click chemistry.

Associated IP will be jointly owned. Under the commercialization agreement, VALANX will produce ClickCRM using its upstream platform technology to incorporate its proprietary synthetic amino acid which harbors a unique chemical group for conjugation. FinaBio will complete the production of ClickCRM using its proprietary purification and formulation methods for CRM197. FinaBio will be responsible for the marketing and commercialization of ClickCRM.

ClickCRM is now available for purchase through FinaBio, along with their existing portfolio of research and GMP-grade carrier proteins.

"The development of ClickCRM demonstrates the functionality of our platform technology for accurate site-specific protein modification, whether for vaccines or therapeutics,” said Michael Lukesch, Founder and Chief Executive Officer at VALANX Biotech. “Combining our platform technology with FinaBio’s proprietary, patented method for expressing and purifying CRM197 allows us to achieve high protein expression levels and excellent incorporation of our non-natural amino acid. This technological advancement will allow vaccine developers to implement ClickCRM in a cost-effective manner to ultimately deliver acceleration and affordability in conjugate vaccine development.”

Andrew Lees, Chief Executive Officer at Fina Biosolutions, added: “Conjugate vaccines represent an effective form of immunization for bacterial infections where the antigen induces a weak immune response. We’re pleased to offer this new product to our customers that will allow them to rapidly produce new conjugate vaccine candidates.” Andrew continued: “FinaBio has been a leader in developing technologies to simplify the manufacture of conjugate vaccines, making these complex vaccines more affordable. By allowing precise, defined conjugation, ClickCRM will meet current quality expectations of regulatory agencies. It is a welcomed addition to our other carrier proteins, including EcoCRM™ (CRM197). It has been a pleasure to collaborate with VALANX Biotech to develop this exciting new product.”

To learn more about ClickCRM, visit https://finabio.net/overview-of-carrier-proteins/


ENDS


Notes to Editors:


ClickCRM™
For a high-resolution image, please contact Zyme Communications.


Media contact

Sarah Jeffery
Zyme Communications
Tel: +44(0) 7771 730919
Email: sarah.jeffery@zymecommunications.com

VALANX Biotech
Michael Lukesch, CEO
Email: lukesch@valanx.bio


To opt out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.


About Valanx Biotech
www.valanx.bio

VALANX Biotech is a biotechnology company dedicated to revolutionizing site-specific protein conjugation and the treatment of various diseases through innovative therapies. The Company is steadfast in its mission to advance innovative protein conjugate therapies that address unmet medical needs for patients and their families worldwide. With a commitment to scientific excellence, VALANX is poised to redefine the treatment landscape and, with lead program VLX101, to make meaningful strides in the fight against autoimmune disorders.


About Fina Biosolutions
https://finabio.net/

Fina Biosolutions is a conjugate vaccine R&D company, providing laboratory services, conjugation technology and consulting. The company was founded in 2006 by Dr. Andrew Lees with the mission of promoting vaccines through the development and sharing of conjugation technology. FinaBio’s conjugation chemistry is used by the Serum Institute of India, GSK and Pfizer, among others. The development of our FinaXpress™ E. coli platform has allowed Finabio to make CRM197 carrier protein more affordable.  The company also serves as a strategic R&D partner and licenses its technology to companies globally.

   
Record changed: 2024-10-29

Advertisement

Picture biomindz Mainz Biomed LSG Colorectal Cancer Screening 650x200px

More documents for Valanx Biotech GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x300px




» top